<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Rimegepant: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Rimegepant: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Rimegepant: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="127257" href="/d/html/127257.html" rel="external">see "Rimegepant: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F54179795"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Nurtec</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F54171755"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antimigraine Agent;</li>
<li>
                        Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist</li></ul></div>
<div class="block doa drugH1Div" id="F54182781"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Concurrent use of rimegepant for both migraine treatment and prevention has not been evaluated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33338437']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33338437'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d36d256f-8d0c-47cc-acaf-2f0f3747bed4">Migraine, moderate to severe, acute treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Migraine, moderate to severe, acute treatment (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Consider use if triptans are contraindicated (eg, cardiovascular risk factors), ineffective, or poorly tolerated. Administration early in the course of a migraine attack, at the first sign of pain, may improve response to treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34160823']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34160823'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>75 mg as a single dose. Maximum: 75 mg per 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31311674','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31311674','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="683d5204-2f9a-4f90-86f2-dc2acc899423">Migraine, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Migraine, prevention (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Avoid use in patients with recent cardiovascular or cerebrovascular ischemic events. Limit use to patients with significant disability from frequent migraines who are unable to tolerate or do not respond to adequate trials of other preventive therapies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29799961','lexi-content-ref-Schwedt.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29799961','lexi-content-ref-Schwedt.2022'])">Ref</a></span>). An adequate trial for assessment of effect is considered to be at least 8 weeks at a therapeutic dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34160823']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34160823'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 75 mg every other day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33338437','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33338437','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F54182783"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">CrCl ≥15 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;15 mL/minute: Avoid use (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">Patients on dialysis: Avoid use (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F54182784"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment (Child-Pugh class A, B): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (Child-Pugh class C): Avoid use.</p></div>
<div class="block doe drugH1Div" id="F54182782"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F54192643"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%: Gastrointestinal: Abdominal pain (≤2%), dyspepsia (≤2%), nausea (2% to 3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Hypersensitivity: Type IV hypersensitivity reaction</p></div>
<div class="block coi drugH1Div" id="F54171758"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity (including delayed serious hypersensitivity) to rimegepant or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F54182752"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity reactions, including dyspnea, rash, and delayed serious reactions, have been reported; discontinue therapy if hypersensitivity occurs.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use is not recommended in patients with severe hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use is not recommended in patients with end-stage renal disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings and precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: The safety of using more than 18 doses in a 30-day period has not been established.</p></div>
<div class="block foc drugH1Div" id="F54179796"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Disintegrating, Oral, as sulfate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nurtec: 75 mg [contains menthol]</p></div>
<div class="block geq drugH1Div" id="F54179794"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F54266796"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, orally-disintegrating</b> (Nurtec Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">75 mg (per each): $149.85</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F54182785"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Using dry hands, peel foil covering blister to remove tablet; do not push tablet through the foil. Immediately place tablet on or under tongue. The tablet will disintegrate in saliva (can be swallowed without additional liquid).</p></div>
<div class="block use drugH1Div" id="F54171757"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Migraine, prevention:</b> Preventative treatment of migraine in adults (Croop 2021; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Migraine, moderate to severe, acute treatment:</b> Acute treatment of migraine with or without aura in adults.</p></div>
<div class="block mst drugH1Div" id="F54182748"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Rimegepant may be confused with rimonabant [multiple international markets].</p>
<p style="text-indent:0em;margin-left:2em;">Nurtec may be confused with Noctec brand name for chloral hydrate [United States, Australia, Canada, United Kingdom]; Nutren brand name for enteral nutrition preparation [multiple international markets]; Nutrex brand name for nutritional supplement [India, Italy].</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F54254508"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of BCRP/ABCG2, CYP2C9 (minor), CYP3A4 (major), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F54254505"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Asciminib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Rimegepant.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Rimegepant.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Rimegepant. Management: If taking rimegepant for the acute treatment of migraine, avoid a second dose of rimegepant within 48 hours when used concomitantly with moderate CYP3A4 inhibitors. No dose adjustment needed if using rimegepant for prevention of episodic migraine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Rimegepant.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elacestrant: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Management: If coadministration with these narrow therapeutic index/sensitive P-gp substrates is unavoidable, separate erdafitinib administration by at least 6 hours before or after administration of these P-gp substrates.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Futibatinib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gilteritinib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lasmiditan: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of Rimegepant. Management: Avoid administration of another dose of rimegepant within 48 hours if given concomitantly with a P-glycoprotein (P-gp) inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pretomanid: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taurursodiol: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F56628972"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">In general, preventive treatment for migraine in patients trying to become pregnant should be avoided. Options for patients planning a pregnancy should be considered as part of a shared decision-making process. Nonpharmacologic interventions should be considered initially. When needed, preventive treatment should be individualized considering the available safety data and needs of the patient should pregnancy occur. A gradual discontinuation of preventive medications is generally preferred when the decision is made to stop treatment prior to conception (ACOG 2022; AHS [Ailani 2021]).</p></div>
<div class="block pri drugH1Div" id="F54182750"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Following oral administration of rimegepant to pregnant rats during the period of organogenesis, adverse fetal events were only observed at doses that also caused maternal toxicity; pre- and postnatal developmental studies in rats were inadequate. Adverse events were not observed following oral administration to pregnant rabbits during the period of organogenesis.</p>
<p style="text-indent:0em;margin-top:2em;">Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist. Based on animal data, CGRP may help regulate placental blood flow, uterine relaxation, and maintain BP; CGRP antagonists could potentially increase the risk of gestational hypertension and preeclampsia (Dodick 2019). The risk of hypertensive disorders, including preeclampsia and eclampsia, are also increased in pregnant patients with migraine (ACOG 2022; Dodick 2019).</p>
<p style="text-indent:0em;margin-top:2em;">In general, preventive treatment for migraine should be avoided during pregnancy. Options for pregnant patients should be considered as part of a shared decision-making process. Nonpharmacologic interventions should be considered initially. When needed, preventive treatment should be individualized considering the available safety data, the potential for adverse maternal and fetal events, and needs of the patient (ACOG 2022; AHS [Ailani 2021]). Oral CGRP receptor antagonists are not currently recommended for the prevention of migraine or treatment of acute migraine in pregnant patients due to lack of data (ACOG 2022).</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to rimegepant is ongoing. Health care providers are encouraged to enroll patients exposed to rimegepant during pregnancy in the Nurtec Pregnancy Registry (877-366-0324 or nurtecpregnancyregistry.com).</p></div>
<div class="block brc drugH1Div" id="F54182751"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Rimegepant is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Data related to the presence of rimegepant in breast milk are available from 12 lactating patients 2 weeks to 6 months postpartum. Patients were administered a single dose of rimegepant 75 mg and breast milk was collected at specified intervals for 36 hours after the dose. The median time to peak concentrations of rimegepant in breast milk was 2 hours after the dose. The maximum concentrations of rimegepant in breast milk and maternal plasma were 169.6 ng/mL and 759.2 ng/mL, respectively. Using the mean milk concentration, authors of the study calculated the estimated exposure to the breastfeeding infant to be 0.005 mg/kg/day (relative infant dose [RID] 0.51% based on a mean maternal dose of 1.04 mg/kg/day). Infants were not breastfed during the study (Baker 2022). In general, breastfeeding is considered acceptable when the RID of a medication is &lt;10% (Anderson 2016; Ito 2000).</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. In general, preventive treatment for migraine in lactating patients should be avoided. When needed, therapy should be individualized considering the available safety data and needs of the patient (AHS [Ailani 2021]). Oral calcitonin gene-related peptide receptor antagonists are not currently recommended for the prevention of migraine or treatment of acute migraine in lactating patients due to lack of data (ACOG 2022).</p></div>
<div class="block pha drugH1Div" id="F54182767"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Rimegepant is a calcitonin gene-related peptide receptor antagonist.</p></div>
<div class="block phk drugH1Div" id="F54182768"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset:</p>
<p style="text-indent:-2em;margin-left:4em;">Migraine treatment: ≤2 hours (Croop 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">Migraine prevention: ≤4 weeks (Croop 2021).</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Migraine treatment: Up to 48 hours (Croop 2019).</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: C<sub>max</sub> decreased 42% to 53% and AUC decreased 32% to 38% following a high-fat meal. C<sub>max</sub> decreased 36% and AUC decreased 28% following a low-fat meal.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: 120 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~96%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Primarily hepatic via CYP3A4 and to a lesser extent by CYP2C9.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: ~64%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~11 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 1.5 hours; delayed 1 hour following a high-fat meal.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (51% as unchanged drug); feces (42% as unchanged drug).</p></div>
<div class="block phksp drugH1Div" id="F54182779"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Hepatic function: C<sub>max</sub> and AUC increased ~2-fold in patients with severe hepatic impairment (Child-Pugh class C) following a single 75 mg dose compared to healthy controls.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58215957"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Nurtec ODT</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Nurtec ODT</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Vydura</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Vydura</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Vydura</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Vydura</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Vydura</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Vydura</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Vydura</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Vydura</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Vydura</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Nurtec ODT</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Vydura</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Vydura</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Vydura</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Vydura</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Nurtec ODT</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Vydura</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Nurtec</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Vydura</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Vydura</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-34160823">
<a name="34160823"></a>Ailani J, Burch RC, Robbins MS; Board of Directors of the American Headache Society. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. <i>Headache</i>. 2021;61(7):1021-1039. doi:10.1111/head.14153<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rimegepant-drug-information/abstract-text/34160823/pubmed" id="34160823" target="_blank">34160823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35576364">
<a name="35576364"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Committee on Clinical Practice Guidelines–Obstetrics. Headaches in pregnancy and postpartum: ACOG clinical practice guideline no. 3. <i>Obstet Gynecol</i>. 2022;139(5):944-972. doi:10.1097/AOG.0000000000004766<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rimegepant-drug-information/abstract-text/35576364/pubmed" id="35576364" target="_blank">35576364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52. doi:10.1002/cpt.377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rimegepant-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35049333">
<a name="35049333"></a>Baker TE, Croop R, Kamen L, et al. Human milk and plasma pharmacokinetics of single-dose rimegepant 75 mg in healthy lactating women. <i>Breastfeed Med</i>. Published online January 18, 2022. doi:10.1089/bfm.2021.0250<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rimegepant-drug-information/abstract-text/35049333/pubmed" id="35049333" target="_blank">35049333</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31311674">
<a name="31311674"></a>Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. <i>Lancet</i>. 2019;394(10200):737-745. doi: 10.1016/S0140-6736(19)31606-X.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rimegepant-drug-information/abstract-text/31311674/pubmed" id="31311674" target="_blank">31311674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33338437">
<a name="33338437"></a>Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. <i>Lancet</i>. 2021;397(10268):51-60. doi:10.1016/S0140-6736(20)32544-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rimegepant-drug-information/abstract-text/33338437/pubmed" id="33338437" target="_blank">33338437</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30661365">
<a name="30661365"></a>Dodick DW. CGRP ligand and receptor monoclonal antibodies for migraine prevention: evidence review and clinical implications. <i>Cephalalgia</i>. 2019;39(3):445-458. doi:10.1177/0333102418821662<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rimegepant-drug-information/abstract-text/30661365/pubmed" id="30661365" target="_blank">30661365</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>NEJM</i>. 2000;343(2):118-126. doi:10.1056/NEJM200007133430208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rimegepant-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29799961">
<a name="29799961"></a>Loder EW, Burch RC. Who should try new antibody treatments for migraine? <i>JAMA Neurol</i>. 2018;75(9):1039-1040. doi:10.1001/jamaneurol.2018.1268<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rimegepant-drug-information/abstract-text/29799961/pubmed" id="29799961" target="_blank">29799961</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nurtec.1">
<a name="Nurtec.1"></a>Nurtec ODT (rimegepant) [prescribing information]. New York, NY: Pfizer Labs; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Schwedt.2022">
<a name="Schwedt.2022"></a>Schwedt TJ, Garza I. Preventive treatment of episodic migraine in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 20, 2022.</div>
</li></ol></div><div id="topicVersionRevision">Topic 127256 Version 71.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
